Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne’s TcBuster for the Development of Luminary’s CAR-T Cell Therapies
FEBRUARY 23, 2021 MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne’s proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the terms of this agreement,... Read more